Treatment with resveratrol attenuates sublesional bone loss in spinal-cord-injured rats


Hua-Dong Wang, Ya-Min Shi, Li Li, Ji-Dong Guo, Yu-Peng Zhang, Shu-Xun Hou


Background and purpose: Sublesional osteoporosis predisposes individuals with spinal cord injury (SCI) to an increased risk of low-trauma fracture. The aim of present work was to investigate the effect of treatment with resveratrol (RES) on sublesional bone loss in spinal-cord-injured rats. Experimental approach: Complete SCI was generated by surgical transaction of the cord at the T10-12 level. Treatment with RES (400 mg/kg body mass/day, intragastrically) was initiated 12 hours after the surgery for 10 days. Then, blood was collected and femurs and tibiae were removed for evaluation of the effects of RES on bone tissue after SCI. Key results: Treatment of SCI rats with RES prevented the reduction of bone mass including bone mineral content and bone mineral density in tibiae, preserved bone structure including trabecular bone volume fraction, trabecular number, and trabecular thickness in tibiae, and preserved mechanical strength including ultimate load, stiffness, and energy in femurs. Treatment of SCI rats with RES enhanced femoral t-SH content, reduced femoral malondialdehyde and IL-6 mRNA levels. Treatment of SCI rats with RES suppressed the upregulation of mRNA levels of PPARγ, aP2, and LPL, and restored mRNA levels of Wnt1, Lrp5, Axin2, ctnnb1, IGF-1 and IGF-1R in femurs and tibiae. Conclusions and Implications: Treatment with RES attenuated sublesional bone loss in spinal-cord-injured rats, associated with abating oxidative stress, attenuating inflammation, depressing PPARγ signaling, and restoring Wnt/β-catenin and IGF-1 signaling.

Link to Article